|
74 Companies |
|
91 Products |
|
91 Products |
|
103 Mechanisms of Action |
|
0 Trials |
|
365 News |
|
| 12345678» |
- | Trial completion, Metastases: Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Sep 9, 2019
P1, N=18, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Trial completion: TRIOC: The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (clinicaltrials.gov) - May 9, 2019
P2, N=94, Completed, Sponsor: University College, London
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | topotecan / Generic mfg., carboplatin / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Apr 20, 2019
P1, N=48, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | CRS-207 / Novartis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: SEASCAPE: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (clinicaltrials.gov) - Apr 4, 2019
P1/2, N=35, Terminated, Sponsor: Aduro Biotech, Inc.
Active, not recruiting --> Completed N=126 --> 35 | Trial completion date: Dec 2018 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Apr 2018; Study was stopped due to low enrollment and lack of clinical activity.
- | Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy (clinicaltrials.gov) - Mar 21, 2019
P=N/A, N=107, Completed, Sponsor: University of Michigan
N=126 --> 35 | Trial completion date: Dec 2018 --> May 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2018 --> Apr 2018; Study was stopped due to low enrollment and lack of clinical activity. Recruiting --> Completed | N=180 --> 107 | Trial completion date: Feb 2020 --> Oct 2017 | Trial primary completion date: Feb 2020 --> Oct 2017
- | Trial completion, Trial completion date, Oncolytic virus: Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 1, 2019
P1, N=37, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed | N=180 --> 107 | Trial completion date: Feb 2020 --> Oct 2017 | Trial primary completion date: Feb 2020 --> Oct 2017 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017
- ||||||| Trial completion, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 6, 2019
P3, N=581, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017 Active, not recruiting --> Completed
- ||| Avastin (bevacizumab) / Roche
Trial completion: BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer (clinicaltrials.gov) - Jan 4, 2019
P=N/A, N=63, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | cisplatin / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, HEOR: Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin (clinicaltrials.gov) - Oct 24, 2018
P=N/A, N=48, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Aug 2018 | Trial primary completion date: Dec 2019 --> Aug 2018
- | Trial completion, Surgery: Continuous Pre-peritoneal Wound Infiltration Versus Epidural Analgesia in Cancer Surgery (clinicaltrials.gov) - Sep 27, 2018
P=N/A, N=40, Completed, Sponsor: Assiut University
Active, not recruiting --> Completed | Trial completion date: Dec 2020 --> Aug 2018 | Trial primary completion date: Dec 2019 --> Aug 2018 Active, not recruiting --> Completed
- | Trial withdrawal, Metastases: ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment (clinicaltrials.gov) - Sep 19, 2018
P2, N=0, Withdrawn, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- | doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial withdrawal: Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children (clinicaltrials.gov) - Jul 20, 2018
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Withdrawn N=28 --> 0 | Not yet recruiting --> Withdrawn
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial completion, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Jul 2, 2018
P2, N=63, Completed, Sponsor: Massachusetts General Hospital
N=28 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children (clinicaltrials.gov) - Jun 26, 2018
P1, N=28, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial completion date: May 2021 --> Aug 2021 | Trial primary completion date: May 2021 --> Aug 2021
- || Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer (clinicaltrials.gov) - Jun 19, 2018
P=N/A, N=63, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: May 2021 --> Aug 2021 | Trial primary completion date: May 2021 --> Aug 2021 Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: May 2018 --> Sep 2018
- | Phase classification, Enrollment change, Trial withdrawal, Trial primary completion date: PET Imaging of Ovarian Carcinoma With 18F-FSPG (clinicaltrials.gov) - Jun 6, 2018
P1, N=0, Withdrawn, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: May 2018 --> Sep 2018 | Trial primary completion date: May 2018 --> Sep 2018 Phase classification: P=N/A --> P1 | N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Aug 2019
- | Trial termination: YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy (clinicaltrials.gov) - Jun 2, 2018
P=N/A, N=2500, Terminated, Sponsor: Gynecologic Oncology Group
Phase classification: P=N/A --> P1 | N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2018 --> Aug 2019 Active, not recruiting --> Terminated
- | metformin / Generic mfg.
Trial completion, Trial completion date: Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients (clinicaltrials.gov) - Jun 1, 2018
P2, N=90, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Terminated Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Jul 2017
- | Trial completion: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Jun 1, 2018
P2, N=100, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial completion date: Feb 2018 --> Jul 2017 Recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer (clinicaltrials.gov) - May 2, 2018
P=N/A, N=63, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Sep 2017 --> May 2018
- | MIS416 / Amplia Therap
Enrollment change, Trial withdrawal: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 1, 2018
P1, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Trial completion date: Sep 2017 --> May 2018 | Trial primary completion date: Sep 2017 --> May 2018 N=12 --> 0 | Recruiting --> Withdrawn
- | Trial primary completion date, Surgery: Continuous Pre-peritoneal Wound Infiltration Versus Epidural Analgesia in Cancer Surgery (clinicaltrials.gov) - May 1, 2018
P=N/A, N=40, Active, not recruiting, Sponsor: Assiut University
N=12 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jul 2017 --> May 2018
- | Sancuso (granisetron) / Solasia
Trial termination: Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=4, Terminated, Sponsor: Gynecologic Oncology Group
Trial primary completion date: Jul 2017 --> May 2018 Suspended --> Terminated; Study terminated due to no patient population available
- | Trial completion, Metastases: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=247, Completed, Sponsor: Gynecologic Oncology Group
Suspended --> Terminated; Study terminated due to no patient population available Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date, Metastases: Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy (clinicaltrials.gov) - Mar 20, 2018
P=N/A, N=180, Recruiting, Sponsor: University of Michigan
Active, not recruiting --> Completed Trial completion date: Feb 2018 --> Feb 2020 | Trial primary completion date: Feb 2018 --> Feb 2020
- | Trial completion date, Trial initiation date, Oncolytic virus: Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 7, 2018
P1, N=37, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Feb 2018 --> Feb 2020 | Trial primary completion date: Feb 2018 --> Feb 2020 Trial completion date: Dec 2017 --> Dec 2018 | Initiation date: Apr 2004 --> Apr 2004
- | topotecan / Generic mfg., carboplatin / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion date, Trial primary completion date: Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 6, 2018
P1, N=48, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Dec 2017 --> Dec 2018 | Initiation date: Apr 2004 --> Apr 2004 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial completion date, Surgery: Continuous Pre-peritoneal Wound Infiltration Versus Epidural Analgesia in Cancer Surgery (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=40, Active, not recruiting, Sponsor: Assiut University
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Jan 2018 --> Mar 2018
- ||| Trial completion date, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Mar 3, 2018
P3, N=586, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jan 2018 --> Mar 2018 Trial completion date: Jan 2018 --> Dec 2018
- | cisplatin / Generic mfg.
Trial primary completion date, HEOR: Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin (clinicaltrials.gov) - Jan 25, 2018
P=N/A, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jan 2018 --> Dec 2018 Trial primary completion date: Dec 2018 --> Dec 2019
- | Folotyn (pralatrexate) / Aurobindo
Trial completion, Phase classification, Trial primary completion date: Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 19, 2018
P1/2, N=50, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed | Phase classification: P2 --> P1/2 | Trial primary completion date: Jan 2018 --> Jul 2016
- | albumin-bound paclitaxel / Generic mfg.
Trial completion, Metastases: Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity (clinicaltrials.gov) - Jan 19, 2018
P1, N=27, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | Phase classification: P2 --> P1/2 | Trial primary completion date: Jan 2018 --> Jul 2016 Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Trial initiation date, Trial primary completion date: Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children (clinicaltrials.gov) - Jan 17, 2018
P1, N=28, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Initiation date: Nov 2017 --> Apr 2018 | Trial primary completion date: Nov 2020 --> Apr 2021
- ||||| Enrollment closed, Trial primary completion date, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jan 16, 2018
P3, N=582, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Initiation date: Nov 2017 --> Apr 2018 | Trial primary completion date: Nov 2020 --> Apr 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2018 --> Jan 2018
- | motesanib (AMG 706) / Takeda
Trial termination: AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 11, 2018
P2, N=23, Terminated, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2018 --> Jan 2018 Completed --> Terminated; Study was stopped for severe toxicity causing concern for patients
- | ketamine / Generic mfg., dexmedetomidine / Generic mfg.
Trial completion, Surgery: Effect of Wound Infiltration by Ketamine Versus Dexmedetomidine Added to Bupivacaine on Surgical Stress (clinicaltrials.gov) - Jan 9, 2018
P3, N=90, Completed, Sponsor: Assiut University
Completed --> Terminated; Study was stopped for severe toxicity causing concern for patients Active, not recruiting --> Completed
- ||| ABT-767 / AbbVie
Trial completion, Enrollment change, BRCA Biomarker, PARP Biomarker, Metastases: Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 2, 2018
P1, N=93, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=75 --> 93
- lenalidomide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 28, 2017
P1/2, N=15, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed | N=75 --> 93 N=51 --> 15 | Suspended --> Terminated | Trial primary completion date: Jun 2013 --> Aug 2011; lack of funding
- | MIS416 / Amplia Therap
Enrollment open: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 28, 2017
P1, N=12, Recruiting, Sponsor: Roswell Park Cancer Institute
N=51 --> 15 | Suspended --> Terminated | Trial primary completion date: Jun 2013 --> Aug 2011; lack of funding Not yet recruiting --> Recruiting
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment closed: TRIOC: The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (clinicaltrials.gov) - Dec 15, 2017
P2, N=97, Active, not recruiting, Sponsor: University College, London
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| CRS-207 / Novartis
Enrollment closed, Combination therapy: SEASCAPE: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer (clinicaltrials.gov) - Dec 14, 2017
P1/2, N=126, Active, not recruiting, Sponsor: Aduro Biotech, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Kinenza (enzastaurin) / Denovo, Aytu BioPharma
Trial completion, Enrollment change, Trial primary completion date: Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 21, 2017
P2, N=28, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=68 --> 28 | Trial primary completion date: Jan 2013 --> Aug 2016
- ||| TroVax (MVA 5T4) / Oxford Biomedica
Enrollment change, Trial primary completion date: TRIOC: The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (clinicaltrials.gov) - Nov 1, 2017
P2, N=97, Recruiting, Sponsor: University College, London
Active, not recruiting --> Completed | N=68 --> 28 | Trial primary completion date: Jan 2013 --> Aug 2016 N=75 --> 97 | Trial primary completion date: May 2017 --> May 2019
- ||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg., nintedanib / Generic mfg.
Trial completion, Combination therapy, Metastases: LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer (clinicaltrials.gov) - Oct 11, 2017
P3, N=1366, Completed, Sponsor: Boehringer Ingelheim
N=75 --> 97 | Trial primary completion date: May 2017 --> May 2019 Active, not recruiting --> Completed
- | Exparel (bupivacaine liposome injectable suspension) / Pacira
Trial initiation date: TAP Versus Thoracic Epidural in Major Abdominal Resections (clinicaltrials.gov) - Oct 10, 2017
P=N/A, N=75, Completed, Sponsor: Spectrum Health Hospitals
Active, not recruiting --> Completed Initiation date: Jul 2014 --> Dec 2013
- | davamotecan pegadexamer (EP0057) / Ellipses Pharma, Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy: CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer (clinicaltrials.gov) - Oct 2, 2017
P2, N=63, Active, not recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Jul 2014 --> Dec 2013 Trial primary completion date: Mar 2017 --> Mar 2018
- | polyvalent vaccine-KLH conjugate / MabVax, Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Combination therapy, IO biomarker: Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (clinicaltrials.gov) - Sep 13, 2017
P=N/A, N=22, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2017 --> Mar 2018 Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Sep 2017
- | polyvalent vaccine-KLH conjugate / MabVax
Trial completion, Trial primary completion date: OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission (clinicaltrials.gov) - Sep 6, 2017
P2, N=171, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Sep 2015
- polyvalent vaccine-KLH conjugate / MabVax, Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, IO biomarker: Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=22, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: Oct 2017 --> Oct 2018
- | Enrollment closed, Surgery: Continuous Pre-peritoneal Wound Infiltration Versus Epidural Analgesia in Cancer Surgery (clinicaltrials.gov) - Aug 16, 2017
P=N/A, N=40, Active, not recruiting, Sponsor: Assiut University
Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Active, not recruiting